Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, B. Gahn, Guido Schumacher et al.|Annals of Oncology|2012Cited by 70
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsChristoph Röllig, Ulrich S. Schuler, Michael Krämer et al.|Annals of Oncology|2018Cited by 37
Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Peter Thuss‐Patience, Michael Kneba, Ralf‐Dieter Hofheinz et al.|Journal of Clinical Oncology|2011Cited by 4
Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ TrialChristoph Röllig, Ulrich S. Schuler, Michael Krämer et al.|Blood|2015Cited by 4
Docetaxel, cisplatin, and capecitabine (DCX) as perioperative chemotherapy in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Peter Thuss‐Patience, Guido Schumacher, Michael Kneba et al.|Journal of Clinical Oncology|2010Cited by 1